213 related articles for article (PubMed ID: 32028983)
21. An integrative approach to identifying cancer chemoresistance-associated pathways.
Chao SY; Chiang JH; Huang AM; Chang WS
BMC Med Genomics; 2011 Mar; 4():23. PubMed ID: 21429228
[TBL] [Abstract][Full Text] [Related]
22. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
23. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
24. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
25. New strategies for targeting drug combinations to overcome mutation-driven drug resistance.
Wang L; Wang H; Song D; Xu M; Liebmen M
Semin Cancer Biol; 2017 Feb; 42():44-51. PubMed ID: 27840276
[TBL] [Abstract][Full Text] [Related]
26. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells.
Wu ZZ; Lu HP; Chao CC
Biochem Pharmacol; 2010 Jul; 80(2):262-76. PubMed ID: 20361941
[TBL] [Abstract][Full Text] [Related]
27. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.
Lin KH; Rutter JC; Xie A; Pardieu B; Winn ET; Bello RD; Forget A; Itzykson R; Ahn YR; Dai Z; Sobhan RT; Anderson GR; Singleton KR; Decker AE; Winter PS; Locasale JW; Crawford L; Puissant A; Wood KC
Nat Genet; 2020 Apr; 52(4):408-417. PubMed ID: 32203462
[TBL] [Abstract][Full Text] [Related]
28. Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.
Stevenson L; Allen WL; Turkington R; Jithesh PV; Proutski I; Stewart G; Lenz HJ; Van Schaeybroeck S; Longley DB; Johnston PG
Clin Cancer Res; 2012 Oct; 18(19):5412-26. PubMed ID: 22859720
[TBL] [Abstract][Full Text] [Related]
29. Molecular and cellular paradigms of multidrug resistance in cancer.
Vaidya FU; Sufiyan Chhipa A; Mishra V; Gupta VK; Rawat SG; Kumar A; Pathak C
Cancer Rep (Hoboken); 2022 Dec; 5(12):e1291. PubMed ID: 33052041
[TBL] [Abstract][Full Text] [Related]
30. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
31. Identification of Drug Resistance Genes Using a Pooled Lentiviral CRISPR/Cas9 Screening Approach.
Kerek EM; Cromwell CR; Hubbard BP
Methods Mol Biol; 2021; 2381():227-242. PubMed ID: 34590280
[TBL] [Abstract][Full Text] [Related]
32. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
[TBL] [Abstract][Full Text] [Related]
33. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Berns K; Bernards R
Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
[TBL] [Abstract][Full Text] [Related]
34. Roles of multidrug resistance genes in breast cancer chemoresistance.
Kuo MT
Adv Exp Med Biol; 2007; 608():23-30. PubMed ID: 17993230
[TBL] [Abstract][Full Text] [Related]
35. Mapping genetic interactions in cancer: a road to rational combination therapies.
Tutuncuoglu B; Krogan NJ
Genome Med; 2019 Oct; 11(1):62. PubMed ID: 31640753
[TBL] [Abstract][Full Text] [Related]
36. In-frame editing of transcription factor gene RDD1 to suppress miR166 recognition influences nutrient uptake, photosynthesis, and grain quality in rice.
Iwamoto M
Sci Rep; 2022 Jun; 12(1):10795. PubMed ID: 35750704
[TBL] [Abstract][Full Text] [Related]
37. Interference with endogenous EZH2 reverses the chemotherapy drug resistance in cervical cancer cells partly by up-regulating Dicer expression.
Cai L; Wang Z; Liu D
Tumour Biol; 2016 May; 37(5):6359-69. PubMed ID: 26631032
[TBL] [Abstract][Full Text] [Related]
38. CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1/P-gp mediated multi-drug resistance (MDR) in cancer cells.
Zhang L; Li Y; Hu C; Chen Y; Chen Z; Chen ZS; Zhang JY; Fang S
Mol Cancer; 2022 Apr; 21(1):103. PubMed ID: 35459184
[TBL] [Abstract][Full Text] [Related]
39. Non-Hodgkin's B-cell lymphoma: advances in molecular strategies targeting drug resistance.
Maxwell SA; Mousavi-Fard S
Exp Biol Med (Maywood); 2013 Sep; 238(9):971-90. PubMed ID: 23986223
[TBL] [Abstract][Full Text] [Related]
40. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
